Laboratory Medicine
Test Directory / Anti-SARS-CoV-2
Anti-SARS-CoV-2
Brown clotted serum, gel barrier
| Test | Anti-SARS-CoV-2 |
|---|---|
| Common Abbreviations | COVID Antibody Test |
| Profile | NA |
| Tube type | Brown clotted serum, gel barrier |
| Clinical Indication | Antibody testing is a key part of the Governments testing programme and will play an increasingly important role as we move into the next phase of responding to this epidemic. A COVID antibody test can tell someone whether they have had the virus that causes Covid-19 in the past, by analysing a blood sample. A positive antibody test demonstrates that someone has developed antibodies to the virus. The presence of antibodies signals that the body has staged an immune response to the virus. There is no evidence yet to suggest that those who have been proven to have had the virus are immune. Individuals should continue to comply with social distancing measures and government guidelines. All infection prevention and control measures must continue to be in place, irrespective of the presence of antibodies. |
| Specimen Type | Blood |
| Sample type | Serum |
| Minimum Volume | 0.5mL If requesting more than 10 tests please send an additional brown clotted serum sample. |
| Special Precautions | No special requirements |
| Stability | Stable for 3 days at 15-25 °C, 7 days at 2-8 °C, 28 days at -20 °C (± 5 °C). Samples may be frozen twice. |
| Turnaround Time | Inpatient: 24 hours |
| Laboratory | York |
| Reference Interval | Interpretive result provided: Negative for anti-SARS-CoV-2 antibodies Positive for anti-SARS-CoV-2 antibodies |
| Limitations | The magnitude of the measured result above the cutoff is not indicative of the total amount of antibody present in the sample. The individual immune response following SARS-CoV-2 infection varies considerably and might give different results with assays from different manufacturers. Results of assays from different manufacturers should not be used interchangeably.The effect of the following pharmaceutical compound on assay performance was tested. Interference was tested up to the listed concentration and no impact on results was observed. Bilirubin (? 1129 µmol/L or ? 66 mg/dL) Haemoglobin (? 1000 mg/dL or ? 10 g/L) Intralipid (? 2000 mg/dL) Biotin (? 4912 nmol/L or ? 1200 ng/mL) Rheumatoid Factors (? 1200 IU/mL) IgG (? 7.0 g/dL or ? 70 g/L) IgA (? 1.6 g/dL or ? 16 g/L) IgM (? 1.0 g/dL or ? 10 g/L) No false negative results due to a high-dose hook effect were found with the Elecsys Anti-SARS-CoV-2 assay but occurrence of high-dose hook effect cannot be completely excluded. In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design. A negative result does not completely rule out the possibility of an infection with SARS-CoV-2. Serum or plasma samples from the very early (pre-seroconversion) phase can yield negative findings. Therefore this test cannot be used to diagnose an acute infection. Also, over time, titers may decline and eventually become negative. |
| Notes | Currently undergoing process of UKAS accreditation |
